The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate-or higer-risk myelodysplastic syndromes in the elderly patients

VernacularTitle:低剂量地西他滨皮下注射治疗老年急性髓系白血病及中高危骨髓增生异常综合征安全性与疗效观察
Author: Hao AI ; Xudong WEI ; Qingsong YIN ; Ping WANG ; Ruihua MI ; Fangfang YUAN ; Lin CHEN ; Yongping SONG
Keywords: Myelodysplastic syndromes; Leukemia; Decitabine; Low dose; Injections,subcutaneous
From: Chinese Journal of Internal Medicine 2017;56(8):606-609
CountryChina
Language:Chinese
Abstract: To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine regimen in patients with acute myeloid leukemia (AML) and intermediate-or higer-risk myelodysplastic syndrome (MDS).Of 6 AML cases,2 achieved complete remission (CR),2 with partial remission(PR),1 with stable disease(SD),1 with progressive disease(PD).As to the 8 MDS patients,one achieved CR and 6 with hematologic improvement (HI),1 case SD.Low dose subcutaneous decitabine regimen could be an alternative choice of older AML or MDS patients.